SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending as the community anticipates potential ETF approval and tokenized stock trading on its platform, with some seeing it as a key to future financial infrastructure. Community members are closely watching meme coins built on Solana, like $UPDOG, $CHINAU, and $401JK, while also discussing network performance and scalability.

1 dog can change your life

1DOG is trending as the community highlights its "magic meme energy" and potential for significant upward movement. Social media buzz suggests it's gaining momentum within the Phantom Wallet ecosystem, with many urging others to buy now. Conversations mention other meme coins like PEPE and SHIB, placing 1DOG within the broader context of speculative cryptocurrency trends.

Bitcoin is the first successful internet money based on peer-to-peer technology; whereby no central bank or authority is involved in the transaction and production of the Bitcoin currency. It was created by an anonymous individual/group under the name, Satoshi Nakamoto. The source code is available publicly as an open source project, anybody can look at it and be part of the developmental process.  Bitcoin is changing the way we see money as we speak. The idea was to produce a means of exchange, independent of any central authority, that could be transferred electronically in a secure, verifiable and immutable way. It is a decentralized peer-to-peer internet currency making mobile payment easy, very low transaction fees, protects your identity, and it works anywhere all the time with no central authority and banks.  Bitcoin is designed to have only 21 million BTC ever created, thus making it a deflationary currency. Bitcoin uses the SHA-256 hashing algorithm with an average transaction confirmation time of 10 minutes. Miners today are mining Bitcoin using ASIC chip dedicated to only mining Bitcoin, and the hash rate has shot up to peta hashes.  Being the first successful online cryptography currency, Bitcoin has inspired other alternative currencies such as Litecoin, Peercoin, Primecoin, and so on.  The cryptocurrency then took off with the innovation of the turing-complete smart contract by Ethereum which led to the development of other amazing projects such as EOS, Tron, and even crypto-collectibles such as CryptoKitties.

Bitcoin

Bitcoin is seeing volatility as the community debates the impact of potential market manipulation and large liquidations. Bullish sentiment persists among some, with some traders anticipating a swift recovery and upward momentum, while others express concern about leverage and potential for further drops. Chatter includes discussion of macro factors such as tariffs and broader market liquidity.

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Innodata is trending due to increasing speculation around potential new contracts and M&A activity, fueled by an upcoming Gen AI summit. The community is closely watching for announcements, with bullish sentiment driven by institutional buying and a lack of insider selling. Broader discussions involve INOD's position in the competitive AI data market and comparisons to industry peers.

ProShares Trust - ProShares UltraPro Short QQQ -3x Shares

ProShares UltraPro Short QQQ

SQQQ is trending as traders discuss potential market corrections and overbought conditions in the tech sector, with some noting high valuations and anticipating a pullback. Community members are actively debating entry points, hedging strategies, and the impact of economic factors like interest rates and government shutdowns. Some traders express frustration with SQQQ's performance, while others remain optimistic about its potential as a hedge against market downturns.

UP Fintech Holding Ltd. is an online brokerage firm that focuses on global investors. It provides an online trading platform that enables investors to trade in equities and other financial instruments on multiple exchanges around the world. The firm offers products and services, as well as a user experience to customers through its mobile first strategy. The company was founded by Tian Hua Wu in June 2014 and is headquartered in Singapore.

UP Fintech Holding Ltd - ADR

TIGR is trending as traders discuss its potential, especially in relation to larger competitor FUTU, as well as its attractive valuation. Community members are weighing in on whether recent price action represents a buying opportunity or a sign of further decline, while some highlight the company's growth and profitability. Recent options activity and technical indicators are also fueling the conversation around potential future movement.

Quoin Pharmaceuticals Ltd. engages in the development of therapeutic products for the treatment of rare and orphan diseases. Its product pipeline includes QRX003, QRX004, QRX007, and QRX008. The company was founded by Michael Myers and Denise Carter on March 5, 2018 and is headquartered in Ashburn, VA.

Quoin Pharmaceuticals Ltd - ADR

Quoin Pharmaceuticals ($QNRX) is trending due to a recently announced private placement that could generate over $100 million. The community is closely watching the stock's volatile price action, particularly the trading halts and potential for a short squeeze. Discussions revolve around whether the funding will fuel long-term growth or if the stock is primed for a pullback.

BHP Group Ltd. engages in the exploration, development, production and processing of iron ore, metallurgical coal, and copper. It operates through the following segments: Copper, Iron Ore, and Coal. The Copper segment refers to the mining of copper, silver, lead, zinc, molybdenum, uranium, and gold. The Iron Ore segment involves in the mining of iron ore. The Coal segment focuses on metallurgical coal and energy coal. The company was founded on August 13, 1885 and is headquartered in Melbourne, Australia.

BHP Group Limited - ADR

BHP is trending due to positive sentiment around the broader metals sector and rising copper futures prices, which recently hit a two-month high. The community is discussing copper's potential to reach new highs, with some anticipating prices between $8-$16 per pound. Additionally, there is discussion around a potential ban on BHP iron ore cargoes in China due to pricing disputes.

Global X Funds - Global X Copper Miners ETF

The Global X Copper Miners ETF ($COPX) is trending as copper prices test new highs, sparking discussions about potential breakouts and future price targets, with some analysts forecasting significant increases. Community members are actively debating whether the ETF is overbought and if a correction is imminent, while others see it as a long-term play due to increasing demand from AI, green energy infrastructure, and potential supply constraints. Some traders are focusing on individual copper mining stocks as well as the ETF, seeking to capitalize on the commodity's momentum.

Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

Protagonist Therapeutics Inc

Protagonist Therapeutics is trending amid reports of positive Phase 2b trial results for their ulcerative colitis treatment, icotrokinra, developed in partnership with Johnson & Johnson. The community is actively discussing the drug's potential, with some speculating about a possible acquisition by J&J, while others focus on target prices and the broader implications for the immunology pipeline.

statis crypto Watchlist

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Vir Biotechnology (VIR) Surges 6.9%: Is This an Indication of Further Gains?

Vir Biotechnology (VIR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Tarsus Pharmaceuticals (TARS) Moves 10.9% Higher: Will This Strength Last?

Tarsus Pharmaceuticals (TARS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Tops Revenue Estimates

Tarsus Pharmaceuticals (TARS) delivered earnings and revenue surprises of -45.45% and +9.94%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Tarsus Pharmaceuticals (TARS) Loses -15.59% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Earnings Outlook For Tarsus Pharmaceuticals

Analyst Ratings For Tarsus Pharmaceuticals

Latest Ratings for TARS
 DateFirmActionFromTo Dec 2021HC Wainwright & Co.Initiates Coverage OnBuy Nov 2021OppenheimerInitiates Coverage OnOutperform Oct 2021Raymond JamesMaintainsStrong Buy...

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives $48.38 Average PT from Analysts

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) has been assigned an average rating of "Moderate Buy" from the eight research firms that are presently covering the stock, MarketBeat...

Insider Selling: Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) General Counsel Sells $135,741.60 in Stock

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS  Get Free Report) General Counsel Bryan Wahl sold 4,436 shares of the firms stock in a transaction dated Monday, March 18th. The stock was sold...

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) COO Sells $149,297.40 in Stock

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS  Get Free Report) COO Seshadri Neervannan sold 4,879 shares of the companys stock in a transaction dated Monday, March 18th. The shares were...

Tarsus Pharmaceuticals (NASDAQ:TARS) Stock Price Up 6.9%

Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS  Get Free Report) rose 6.9% on Friday . The stock traded as high as $31.73 and last traded at $31.47. Approximately 103,785 shares changed...

Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of therapeutic candidates. Its product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of blepharitis caused by the infestation of Demodex mites, which is referred to as Demodex blepharitis. It is also developing TP-04 for the potential treatment of Ocular Rosacea and TP-05 as an oral tablet for the potential prevention of Lyme disease. The company was founded by Bobak Azamian and D. Michael Ackermann in 2017 and is headquartered in Irvine, CA.

Tarsus Pharmaceuticals Inc

Will JP Morgan Chase ($JPM) beat quarterly earnings?  
 
*Powered by Polymarket

Stocktwits

JPMorgan Chase & Co

) beat quarterly earnings?  
 
*Powered by Polymarket

Current Price	$70.14
Prev Close	$70.38
Open	$70.20
Dividend Yield	0.00%
50-Day Moving Average	$55.52
Beta	0.78
Avg. Volume	738,594.38
PE Ratio	-30.13

52-Week High	$70.78
52-Week Low	$35.34
Market Capitalization	$2.96B
EPS (Annual)	-$3.07
Price to Book	8.90
Revenue Per Employee	$566,417.96
Enterprise Value/EBITDA	N/A

TARS
Tarsus Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest TARS News

TARSTarsus Pharmaceuticals Inc